eligibility_summary
Eligible: adults (≥18) with pathologically confirmed advanced solid tumors, measurable lesion(s) not limited to brain/bone, tumor tissue available, ECOG 0–1, life expectancy ≥12 weeks, contraception/negative pregnancy test, consent. Exclude: prior B7‑H4 tx, recent anticancer therapy, ≥G2 toxicities, effusion needing care, other malignancy, brain mets/meningitis, major organ dysfunction, uncontrolled DM/HTN, bleeding, recent infection, prolonged steroids/immunodef/transplant, HBV/HCV/TB/HIV/syphilis, Child‑Pugh B+, severe neuro/psych, pregnancy, recent live vaccine, active autoimmune, recent GI fistula/perf/obstruction, noncompliance, any safety concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests HS-20089-based combinations in advanced solid tumors. Interventions and mechanisms: 1) HS-20089: antibody–drug conjugate (ADC). Humanized IgG1 anti–B7-H4 mAb linked via protease-cleavable linker to a topoisomerase I inhibitor (DAR ~6). Binds B7-H4 on tumor cells, internalizes, releases topo I payload to induce DNA damage and tumor cell death. Targets: B7-H4–expressing tumor cells, topoisomerase I/DNA replication. 2) Adebrelimab: anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor) blocking PD-1/PD-L1, restoring T-cell activity. Targets: PD-L1 on tumor/immune cells, T-cell activation pathways. 3) Bevacizumab: anti–VEGF-A monoclonal antibody (anti-angiogenic) inhibiting VEGF signaling to reduce tumor angiogenesis and permeability. Targets: VEGF/VEGFR pathway in endothelial cells. 4) Cisplatin/Carboplatin: platinum chemotherapies causing DNA crosslinks. Targets: tumor cell DNA and DNA-damage response pathways.